A 60-year-old man was admitted to our hospital for the treatment of multiple liver tumors. A tumor biopsy revealed neuroendocrine tumor (NET) with a low Ki-67 index ([Picture A](#g001){ref-type="fig"}). Positron emission tomography-computed tomography clarified that the primary lesion was located in the ileum. The patient had undergone 3 cycles of peptide receptor radionuclide therapy (PRRT) with (177) Lu-DOTATATE ([@B1]) and 15 cycles of a chemotherapeutic regimen consisting of capecitabine and temozolomide (CAPTEM) ([@B2]). However, progressive disease resulting in multiple liver tumors was observed ([Picture B](#g001){ref-type="fig"}). At this time, the patient underwent hepatic arterial chemoembolization using drug-eluting beads (DEB-TACE: Epirubicin-loaded DC Bead^Ⓡ^). Two months later, the blood flow to the liver tumors had completely disappeared ([Picture C](#g001){ref-type="fig"}). We found that DEB-TACE was a feasible treatment for multiple liver tumors arising from a NET in a patient who had not responded to PRRT or CAPTEM.
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